左甲状腺素吸收试验:梅奥诊所四年经验(2015-2018)
该研究回顾了梅奥诊所2015年1月至2019年1月间16例难治性甲状腺功能减退症患者的病历,这些患者完成了左甲状腺素吸收试验(LT4AT)。主要目的是评估该试验区分LT4吸收不良与假性吸收不良的效用,次要目的包括对医生管理决策的影响及随访临床结局。结果显示,13例可计算吸收率的患者中,1例吸收受损(吸收率0%),12例在试验第4小时吸收正常(吸收率60-158%)。
要点
- LT4AT可帮助区分LT4吸收不良与假性吸收不良。
- 正常吸收标准为吸收率≥60%,且需结合TT4趋势至少4小时。
- 吸收不良患者静脉LT4治疗可改善。
核心结论
- LT4AT可为区分LT4吸收不良与假性吸收不良提供有价值的信息。
- 研究支持在判断吸收情况时结合计算出的吸收百分比与至少4小时的TT4趋势。
研究设计与样本
- 回顾性病历 review,纳入2015年1月至2019年1月间16例诊断为难治性甲状腺功能减退症并完成LT4AT的患者。
- LT4AT为六小时试验,患者接受基于体重的LT4剂量,随后系列测量总甲状腺素(TT4)和促甲状腺激素(TSH)。
- 吸收百分比计算公式见原文,正常吸收定义为≥60%。
主要发现
- 16例患者中13例因缺乏TT4数据而可计算吸收百分比。
- 1例患者吸收受损(吸收百分比=0),该患者有已知的吸收不良原因。
- 其余12例患者在试验第4小时吸收正常(吸收百分比60-158),同时TT4呈上升趋势。
- 临床随访范围1至32个月(中位数6.5个月),11例有随访数据。
- 随访中6例最近TSH正常或抑制,4例TSH升高但有改善;1例吸收不良患者经静脉LT4治疗改善。
关键数值与推荐
- 正常吸收定义为吸收百分比≥60%。
- 吸收百分比计算公式见原文。
临床怎么用
- 对于难治性甲状腺功能减退症患者,可考虑使用LT4AT区分吸收不良与假性吸收不良。
- 判读结果时应结合计算出的吸收百分比与至少4小时的TT4趋势。
局限性
- 回顾性研究,样本量小(16例)。
- 3例患者因缺乏TT4数据无法计算吸收百分比。
- 随访数据仅11例患者有。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Levothyroxine (LT4) is the mainstay of therapy for hypothyroidism. Yet, despite physician efforts at dose titration, some patients remain hypothyroid on LT4 doses in excess of weight-based calculations, a condition known as refractory hypothyroidism. The LT4 absorption test (LT4AT) has been proposed to have utility in these patients by enabling distinction of LT4 malabsorption from pseudomalabsorption, a condition of intentional nonadherence. Given its rare use in clinical practice, we reviewed our institution's experience with the LT4AT to assess its impact on management of refractory hypothyroidism. Methods: We reviewed the charts of 16 patients diagnosed with refractory hypothyroidism and who had completed the LT4AT between January 2015 to January 2019. The primary aim was to determine the utility of this test in distinguishing LT4 malabsorption from pseudomalabsorption. Secondary aims were to determine whether the results of this test impacted physicians' management decisions, as well as to report on clinical outcomes at follow-up. Our LT4AT is a six-hour test wherein patients receive a weight-based dose of LT4 followed by serial measurements of total thyroxine (TT4) and thyrotropin (TSH). Percentage absorption is calculated using the following formula, with normal absorption being ≥60%: [Formula: see text] Results: Percentage absorption was calculated in 13 of 16 patients due to lack of TT4 data for 3 patients. Absorption was impaired in one patient (% absorbed = 0), who had known causes of malabsorption. The remaining 12 patients had normal absorption by hour 4 of the test (% absorption 60-158) in conjunction with upward TT4 trends. Clinical follow-up ranged from 1 to 32 months (median 6.5 months), with 11 patients having follow-up data. Six of these had normal or suppressed TSH values at most recent follow-up, and four had improved but persistent TSH elevations. The one said patient with malabsorption improved with intravenous LT4. Conclusions: The LT4AT can provide valuable information for distinguishing malabsorption from pseudomalabsorption. Our findings support the combined use of calculated percentage absorptions with TT4 trends for at least a four-hour time frame when making determinations regarding absorption.
引用
- Gonzales KM, Stan MN, Morris JC, et al. The Levothyroxine Absorption Test: A Four-Year Experience (2015-2018) at The Mayo Clinic. Thyroid. 2019. PMID: 31680654. doi:10.1089/thy.2019.0256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。